<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT01687699</url>
  </required_header>
  <id_info>
    <org_study_id>dohas01</org_study_id>
    <nct_id>NCT01687699</nct_id>
  </id_info>
  <brief_title>Effects of Spironolactone on Cardio- and Cerebrovascular Morbidity and Mortality in Hemodialysis Patients</brief_title>
  <sponsors>
    <lead_sponsor>
      <agency>Dialysis Outcomes Heart Failure Aldactone Study Group</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Dialysis Outcomes Heart Failure Aldactone Study Group</source>
  <brief_summary>
    <textblock>
      Aldosterone receptor blockers reduce cardiac-related morbidity and mortality. Recently, we
      demonstrated that long-term low-dose spironolactone is clinically safe in many hemodialysis
      (HD) patients. In the present study, we assess whether low-dose spironolactone treatment
      reduces the high incidence of cardio- and cerebrovascular (CCV) morbidity and mortality in HD
      patients. The investigators' hypothesis is that aldosterone receptor blockade by
      spironolactone reduces the risk of both CCV morbidity and death among HD patients.
    </textblock>
  </brief_summary>
  <overall_status>Completed</overall_status>
  <start_date>April 2008</start_date>
  <primary_completion_date type="Actual">December 2008</primary_completion_date>
  <phase>Phase 4</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Prevention</primary_purpose>
    <masking>Single (Outcomes Assessor)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>cardio- and cerebrovascular events</measure>
  </primary_outcome>
  <secondary_outcome>
    <measure>death from all causes</measure>
  </secondary_outcome>
  <number_of_arms>1</number_of_arms>
  <enrollment type="Actual">157</enrollment>
  <condition>End-stage Renal Failure</condition>
  <arm_group>
    <arm_group_label>spironolactone</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Spironolactone</intervention_name>
    <arm_group_label>spironolactone</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Hemodialysis patients undergoing 4-hour-long HD thrice a week for at least 2 years

          -  With an average serum potassium level (immediately before dialysis on the first day of
             the week) of &lt;6.5 mEq/l over the previous 2 months

          -  With a 24-hour urine output of &lt;500 ml

        Exclusion Criteria:

          -  A history of noncompliance

          -  Unstable vascular access

          -  Hypotension

          -  Hepatic failure

          -  Active cancer

          -  Any life-threatening disease other than ESRD
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>30 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
  </eligibility>
  <location>
    <facility>
      <name>Shibukawa Clinic</name>
      <address>
        <city>Shizuoka</city>
        <zip>424-0053</zip>
        <country>Japan</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Japan</country>
  </location_countries>
  <link>
    <url>http://www.ncbi.nlm.nih.gov/pubmed/19342857</url>
  </link>
  <verification_date>September 2012</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>September 12, 2012</study_first_submitted>
  <study_first_submitted_qc>September 14, 2012</study_first_submitted_qc>
  <study_first_posted type="Estimate">September 19, 2012</study_first_posted>
  <last_update_submitted>September 14, 2012</last_update_submitted>
  <last_update_submitted_qc>September 14, 2012</last_update_submitted_qc>
  <last_update_posted type="Estimate">September 19, 2012</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>Dialysis Outcomes Heart Failure Aldactone Study Group</investigator_affiliation>
    <investigator_full_name>Yoshihiro Matsumoto</investigator_full_name>
    <investigator_title>MD., PhD.</investigator_title>
  </responsible_party>
  <keyword>cardiovascular event</keyword>
  <keyword>hemodialysis</keyword>
  <keyword>spironolactone</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Renal Insufficiency</mesh_term>
    <mesh_term>Kidney Failure, Chronic</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Spironolactone</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

